Indium In-111 pentetreotide

Summary

Indium‑111 pentetreotide (OctreoScan) is a radiolabelled somatostatin analogue used as a diagnostic imaging tracer. After intravenous injection, it binds to somatostatin receptor subtype 2 on neuroendocrine and certain paraganglioma cells, allowing gamma‑camera scintigraphy to locate primary tumors and metastases. It is employed in both human and veterinary medicine for conditions such as insulinomas, carcinoid tumors, carotid body tumors, and orbital metastases from neuroendocrine cancers.

Mechanism of Action

The molecule consists of the peptide octreotide, a synthetic analogue of somatostatin, conjugated to the chelator DTPA and labeled with the gamma‑emitting radionuclide indium‑111. Octreotide has high affinity for somatostatin receptor subtype 2 (sst2), which is over‑expressed on many neuroendocrine tumors. After intravenous administration, the tracer circulates, binds to sst2‑positive cell membranes, and remains localized. Decay of indium‑111 emits photons detectable by planar or SPECT scintigraphy, producing images that reflect receptor density and tumor location.

What the Research Shows

Published investigations demonstrate the imaging capabilities of indium‑111 pentetreotide across species and tumor types. In dogs with insulinoma, scintigraphy identified somatostatin‑receptor‑positive lesions and aided surgical planning, although precise lobar localization was inconsistent (Garden 2005; Lester 1999). In five patients with carotid body tumors, the tracer confirmed diagnosis and detected no recurrence after surgery (Hammond 1997). A case report of an orbital metastasis from a gastrointestinal neuroendocrine tumor showed concordant uptake on fused MR‑SPECT images, supporting its diagnostic value (Beam 2019). In a cohort of 29 human neuroendocrine tumor patients, indium‑111 pentetreotide findings complemented FDG‑PET/CT; normal pentetreotide scans were associated with a non‑significant trend toward longer survival, while PET/CT abnormalities predicted poorer prognosis (Zalom 2009). Collectively, these data indicate that the tracer is useful for tumor detection, staging, and monitoring, particularly when receptors are expressed.

Reported Benefits

Indium‑111 pentetreotide provides a non‑invasive method to visualize somatostatin‑receptor‑positive tumors, facilitating diagnosis, surgical planning, and assessment of metastatic spread. It can detect lesions not readily seen on conventional CT or MRI, as shown in carotid body tumors and orbital metastases. In veterinary practice, it supports insulinoma identification where biochemical tests alone are insufficient. When combined with FDG‑PET/CT, it offers complementary metabolic and receptor information that may improve prognostic stratification.

Limitations of the Evidence

Tracer uptake depends on sst2 expression; tumors lacking receptors may yield false‑negative scans, as observed in some canine insulinomas where localization was equivocal. Sensitivity varies, and precise anatomical localization (e.g., pancreatic lobe) can be limited. Evidence largely derives from small case series and retrospective analyses, restricting generalizability. Comparative studies suggest FDG‑PET/CT may better predict outcomes, indicating that indium‑111 pentetreotide alone is insufficient for prognostication. Availability of hybrid SPECT/CT imaging is not universal, potentially limiting clinical implementation.

Safety Considerations

Safety data in the cited literature are sparse, but indium‑111 pentetreotide is a radioactive drug administered intravenously, exposing patients to ionizing radiation comparable to other nuclear‑medicine scans. Reported adverse events are rare; no acute toxicity was described in the animal or human studies. Caution is advised in pregnant or lactating individuals due to fetal radiation risk, and in patients with severe renal impairment where clearance may be altered. Standard radiation protection guidelines should be followed.

How It Is Administered

The tracer is supplied as indium‑111‑labeled DTPA‑octreotide for intravenous injection. After administration, planar or SPECT scintigraphy is typically performed at multiple time points ranging from 1 to 24 hours to capture optimal tumor uptake, as described in canine studies. Imaging equipment includes gamma cameras equipped for indium‑111 photon energies. No oral or other routes are used.

Routes of Administration

Goals & Uses

• Detection of occult primary NETsDiagnostic ImagingModerate
• Monitoring treatment responseOncology DiagnosticsModerate
• Staging and restaging of neuroendocrine tumorsOncology DiagnosticsHigh
• Neuroendocrine tumor imagingDiagnosisHigh
• Patient selection for somatostatin analogue therapyTheranosticsModerate
• Localization of neuroendocrine tumorsDiagnostic ImagingHigh

Contraindications

• Known hypersensitivity to octreotide or pentetreotideAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Known hypersensitivity to pentetreotide or any componentAllergyHigh
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data

Adverse Effects

• Radiation exposureRadiologicalUnknown
• Dizziness / headacheNeurologicalUncommon
• Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
• Hypersensitivity / anaphylaxisImmunologicalRare
• Injection site reactionsLocalUncommon
• HypotensionCardiovascularUncommonLow blood pressure
• FlushingVascularCommonWarmth and redness of the skin
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Hypoglycemia or hyperglycemiaMetabolicRare

Drug Interactions

• Total parenteral nutrition / lipid emulsionsLow
• Somatostatin analog therapy (e.g., octreotide)Low
• Octreotide (therapeutic doses)High
• LanreotideHigh
• Other radiopharmaceuticalsModerate

Population Constraints

• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Breastfeeding womenReproductiveAbsolute
• Pregnant womenReproductiveAbsolute
• Diabetic PatientsMetabolicRelative

Regulatory Status

• European UnionApprovedApproved: Diagnostic imaging of SSTR‑positive neuroendocrine tumors
• United StatesApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsMarketed as OctreoScan.
• United KingdomApprovedApproved: SPECT imaging of neuroendocrine tumors expressing somatostatin receptors

FDA‑approved (2003) for imaging of SSTR‑positive tumors; marketed as OctreoScan.

Evidence & Sources

• Scintigraphic diagnosis of insulinoma in a dog
  Journal ArticleLowLester NV, et al.1999-01-01T00:00:00.000000Z
• Rare Orbital Metastasis Originating From a Neuroendocrine Tumor
  Journal ArticleLowBeam AS, et al.2019-01-01T00:00:00.000000Z
• Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide
  Journal ArticleLowZalom ML, et al.2009-01-01T00:00:00.000000Z
• Somatostatin receptor imaging in vivo by planar scintigraphy facilitates the diagnosis of canine insulinomas
  Journal ArticleLowGarden OA, et al.2005-01-01T00:00:00.000000Z
• Indium In-111 pentetreotide scintigraphy: application to carotid body tumors
  Journal ArticleLowHammond SL, et al.1997-01-01T00:00:00.000000Z

Frequently Asked Questions